Picture of RegenETP, logo

RGTPQ — RegenETP, News Story

0.000.00%
us flag iconLast trade - 00:00
FinancialsHighly SpeculativeMicro Cap

PolarityTE Inc expected to post a loss of $1.25 a share - Earnings Preview

* PolarityTE Inc  PTE.OQ   PTE.O  is expected to show a fall
in
quarterly revenue when it reports  results on August 11. 
    * The Salt Lake City Utah-based  company is expected to
report  a
75.9% decrease in revenue to $612.5 thousand from $2.54 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for PolarityTE Inc is
for a
loss of $1.25 per share. For the same quarter last year, the
company reported a loss of 100 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PolarityTE
Inc is
$23.75​, above​ its last closing price of $1.56. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -2.17       -2.12      -2.25     Missed  -5.9
 Dec. 31 2022              -2.33      -2.75     Missed  -17.9
 Sep. 30 2021  -2.42       -2.92      -0.25     Beat    91.4​
 Jun. 30 2021  -2.23       -2.42      -1.00     Beat    58.6
 ​​Mar.        -3.18       -2.92      -4.00     Missed  -37.1
 31 2021                                                
 Dec. 31 2020  -5.75       -4.12      -6.50     Missed  -57.6​
 Sep. 30 2020  -4.91       -5.15      -4.50     Beat    12.6
 Jun. 30 2020  -8.86       -9.42      -8.25     Beat    12.4
 This summary was machine generated August 10 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on RegenETP,

See all news